Cargando…
Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.(1)
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313925/ https://www.ncbi.nlm.nih.gov/pubmed/37343514 http://dx.doi.org/10.1016/j.xcrm.2023.101071 |